Financial News

Disappointing study results for Nivalis Therapeutics

Nivalis Therapeutics Inc. (Nasdaq: NVLS) reported disappointing results from a Phase 2 clinical trial of its cystic fibrosis treatment cavosonstat. Shares of the pharmaceutical plunged $3.68 to close at $2.57.



Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Feedback